Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease progression

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Merck’s Keytruda approved by EC for two new gastrointestinal cancer indications

Both approvals follow recommendations from the European Medicines Agency’s human medicines committee

- PMLiVE

EC, HMA and EMA publish first version of Union list of critical medicines

The established list aims to prevent potential future shortages of critical medicines in the EU

- PMLiVE

Astellas’ menopause drug granted EC approval to treat vasomotor symptoms

More than half of women aged 40 to 64 years experience symptoms such as hot flashes

EU flag

EC approves Blueprint’s Ayvakyt as first treatment for rare haematological disorder

The therapy targets the primary underlying cause of indolent systemic mastocytosis

- PMLiVE

GSK’s Jemperli combination receives EC approval for endometrial cancer

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

Medscape Education Redefines Standards with Website Redesign

Medscape Education—the number 1 destination for CME—--has launched a redesign of its education hub. The site now features easy-to-navigate categories, a highlight on curricula, and enhanced search capabilities, allowing Medscape...

Medscape Education Global

- PMLiVE

Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

The candidate is currently in late-stage development for tenosynovial giant cell tumour

- PMLiVE

UK-India research project trialling easy-to-use UTI test to support fight against AMR

AMR has been declared by WHO as one of the top ten threats to global public health

- PMLiVE

New study finds dose of subcutaneous cladribine could predict MS relapse risk

The disease affects approximately 130,000 people in the UK and currently has no cure

- PMLiVE

New blood test to reduce heart attacks and death rates in A&E heart patients

The test could improve diagnosis for one in five patients with a heart muscle injury

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links